Asthma is a chronic inflammatory disorder of the airways characterized by participation of many inflammatory cells and cell elements. The research in asthma pharmacotherapy is currently focused on the classic therapy optimization and at the same time on the selective modulation of mechanism control the immune system function. The aimed therapy or „biological therapy“ affected the function of specific immune cells, which participate in immune system regulation. Antagonists of inflammatory cytokines IL-4, IL-5 and TNF-α were used in experimental and clinical studies for asthma therapy. Anti-IgE-therapy with IgE monoclonal antibodies or specific allergen immunotherapy is introduced in clinical practice.